Bausch+Lomb Results Presentation Deck
Total Bausch+Lomb P&L¹ (GAAP)
Bausch + Lomb
Vision Care Revenue
Surgical Revenue
Ophthalmic Pharmaceuticals Revenue
Total Revenue
Gross Profit
Gross Margin
R&D
R&D percent of Revenues
SG&A
SG&A percent of Revenues
Operating Income
Depreciation
Stock Based Compensation
Net Income
Net Income Margin
EPS³
1Q22
$560M
$174M
$155M
$889M
$476M
53.5%
$77M
8.7%
$343M
38.6%
$54M
$30M
$16M
$20M
2.2%
$0.06
BAUSCH + LOMB 1. Products with sales outside the United States impacted by F/X changes.
1Q21
$556M
$162M
$163M
$881 M
$471M
53.5%
$67M
7.6%
$318M
36.1%
$85M
$30M
$14M
$27M
3.1%
$0.08
2. This is a non-GAAP measure or ratio. See Slide 2 and Appendix for further information on non-GAAP measures and ratios.
3. On a proforma basis after giving effect to the IPO.
Reported Change
1%
7%
(5%)
1%
1%
0 bps
(15%)
(8%)
(36%)
0%
(14%)
(26%)
Constant Currency²
4%
11%
(3%)
4%
4%
(18%)
(11%)
(33%)
3%
(14%)
(15%)
Organic Change²
4%
13%
(3%)
5%
9View entire presentation